Sensitivity of Xpert® HPV in predicting pathology-confirmed CIN2+ was high for both self-and clinician-collected samples in HIVpositive and HIV-negative women (Table 2 ). However, specificity was lower for HIV-positive compared with HIV-negative women and in self-rather than clinician-collected samples. Changing the definition of screen positivity to include samples testing positive on any of the first three channels, i.e. HPV types 16, 18/45 or 31/33/35/52/58, rather than all five led to a very slight decrease in sensitivity but improved specificity to over 90% for cliniciancollected samples in HIV-negative women and over 70% in HIV-positive women.
Conclusion
HPV prevalence was high in HIV-positive women in our study population (49.2%). Xpert® HPV screening is highly sensitive in predicting pathology-confirmed CIN2+ but has limited specificity in HIV-positive women. Restricting the definition of screen positivity to the first three channels covering HPV types 16, 18/45 and 31/33/35/52/58 improved specificity in HIV-positive women, with minimal loss of sensitivity. This is of potential clinical utility in improving positive predictive value and reducing the number of women requiring further investigation.
Practical considerations around using Xpert® HPV in low-income countries, focusing on Malawi 
Background
The worldwide burden of HPV-associated disease is concentrated in resource-constrained countries. Around 85% of all cervical cancers occur in these areas (see Figure 1) and it is the most common form of cancer in sub-Saharan Africa, South Asia and parts of Latin America. Additionally, almost nine out of 10 cervical cancer deaths occur in resource-constrained countries [1] . Devastatingly, it affects women in their prime child-bearing and productive years, and disproportionately affects the poorest and most vulnerable. As world population and life expectancy grow, the International Agency for Cancer Research predicts a 40% increase in cervical cancer by 2020.
Interventions based on cervical screening and HPV vaccination of girls can hugely influence country-level outcomes. Visual inspection with acetic acid (VIA) is the cornerstone of current screening as it is cheap, non-invasive and can be executed in low-tech health facilities with instant results. It is recommended by WHO [2] and has been adopted by 26 countries as their national screening strategy [3] . However, VIA is subjective, with high variability between evaluators even in quality settings. Low-grade lesions show as aceto-white, leading to overtreatment. HPV testing is more effective than VIA in reducing the prevalence of cervical intraepithelial neoplasia grades 2, 3 or cancer (CIN2+) [4] .
The highest cervical cancer prevalence in the world is in Malawi, where it is the commonest cancer in women, accounting for 45% of cancers. The Ministry of Health estimates that if nothing is done, cases will increase by 60% by 2025. Malawi has a policy for VIA but this is difficult to deliver. We sought to deliver a same day 'screen and treat' programme using VIA and thermo-coagulation for treatment of early lesions [5] .
Choice of HPV test is a difficult issue for low-and middle-income countries (LMIC) such as Malawi. A 2016 study [6] concluded that the 'HPV test global market is one of the most confusing, least regulated and with the most divergent products on the market'. Figure 1 . Age-standardised cervical cancer incidence and mortality rates by world area. Reproduced from [1] 'screen and treat' strategy, using testing as triage to VIA and treatment. We chose Xpert® HPV in the light of its strengths and weaknesses (see Table 1 ) [7] .
Methods
We initially measured prevalence of high-risk HPV in routinely screened women using Xpert® HPV in accordance with the manufacturer's instructions, i.e. with PreservCyt® (PC) 20 mL in ThinPrep® pots. We then compared results with those obtained using alternative media and collection volumes and devices. We initially tried infusion saline because of delayed delivery of PC, but also investigated Natrol® and NOVAprep HQ+ Orange®, and self-collection of vaginal samples using cotton swabs, Quintips® and Vibabrushes®.
Results
Prevalence of HPV was 19.9% as shown in Table 2 , with HPV 31/33/35/52/58 accounting for 40.1% of positive results. The age distribution of HIV and HPV positivity was as expected, with peak HPV incidence between 20 and 39, and peak HIV between 20 and 49. In terms of VIA outcomes, treatable lesions were predominantly seen in the 20-39 age group, with cancers and suspicious cancers at least a decade later.
Results of comparison testing using different collection media were as shown in Table 3 with saline, Natrol® and NOVAprep HQ+ Orange® all showing quite high Kappa values for agreement with PC despite relatively small numbers. Self-collection of vaginal samples was highly acceptable to women, and gave similar levels of HPV positivity when collected into PC with cotton swabs, Quintips® or Vibabrushes®. As with any HPV test, positivity rates were slightly higher for self-collected than clinician collected samples. We found 5 mL of PC was adequate for reproducible results. Plain cotton swabs (n=125) were by far the cheapest and gave remarkably comparable results provided that they were collected into PC and not sent dry to the laboratory. Quintips® (n=216) were easy to use with the manufacturer's or standard blood collection tubes and 4-5 mL PC added at the laboratory. Vibabrushes® (n=133) gave more invalid results in this small study, suggesting women found these harder to use. Further data were presented on Poster 143.
Discussion
Collection of 12 mL (NOVAprep HQ+ Orange®) or 20 mL (ThinPrep®) specimens in media designed for cytology is wasteful in LMIC. Collection systems including pots suited for cytology with cervix brushes are unnecessary, expensive and contain more plastic than desirable for disposal. Although sterile saline gave acceptable results in this small study, because of the potential for contamination it is unsuitable where transportation of samples is required. NOVAprep HQ+ Orange® gave the best HPV test result agreement with PC, and has a longer storage life (3 months rather than 3 weeks for clinical specimens) because it contains ethanol rather than methanol. However, a simpler medium would be preferable and we found only 5 mL of PC was needed for comparable results with provider-collected samples. Self-collection of vaginal samples was acceptable to women in Nkhoma and plain cotton swabs gave reasonable detection of HPV if collected directly into medium in the clinic. Quintips® provided a simple, consistent system when used with manufacturer's or standard blood collection tubes, which are always available. This is easily transportable and it is straightforward for the laboratory to add 4-5 mL medium after arrival.
In conclusion, Xpert® HPV is straightforward to use with rapid turnaround and could potentially be offered as a near-patient test by clinical rather than laboratory staff. It should now be validated with larger numbers using self-taken vaginal samples and low-cost collection systems in LMIC. We owe it to girls, and their mothers and grandmothers, in Malawi and many other countries to advance not just the introduction of vaccine but also relevant HPV testing in 'screen and treat' programmes. My personal recommendations are that:
■ All manufacturers, not just Cepheid, should agree universal collection systems, suitably priced for LMIC and not tied to a single test.
■ Manufacturers should validate tests against a wider range of collection media, including simple, inexpensive media for use in LMIC.
■ HPV tests should be as technically straightforward as possible for small laboratories or clinic staff to perform with minimal staff training.
■ Turnaround time should be compatible with a single day visit and thus with 'see and treat' programmes.
■ Discounted prices for LMIC are essential to achieve widespread implementation as prioritised by the Sustainable Development Goals. ■ Must be validated for primary population-based screening.
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■ Assay must contain a control to monitor inhibition and/or assay failure, and a control for cellularity to detect inadequate or empty cervical samples -these may be the same, e.g. beta-globin.
■ Self-collected specimens must be tested using a PCR test.
We specified HC2 or an equivalent test because there are very few working HC2 systems in Australia, which is a large developed country. In addition, following analysis of data from our Compass trial of 121,000 women comparing liquidbased cytology to HPV screening, we require a minimum of 2000 screening tests to be assessed while samples remain valid for retesting (both HPV and cytology) to monitor positivity rates for HPV. This is viewed as an important safeguard for the program in Australia because in 2009 a change in the buffer for our bowel cancer screening program led to a drop in the positivity rate, resulting in suspension of the entire program for 6 months. Thus far five assays have been identified as fitting the criteria, and in order of publication these are the Roche cobas® 4800 [2] , Abbott RealTime [3] , BD Onclarity™ [4] , Seegene Anyplex™ II [5] and Cepheid GeneXpert® HPV* [6] . Other tests are expected also to meet the criteria for approval. In terms of genotyping, cobas® 4800 and RealTime detect HPV 16, 18 or other (which includes the other 12 oncogenic types), Onclarity™ groups the 14 oncogenic types into nine groups while Xpert® presents the 14 oncogenic types in five groups. Anyplex™ II presents the 14 oncogenic HPV types individually. Technical and laboratory considerations are as shown in Table 1 .
Self-collection as an alternative pathway for under-screened women
In Victoria, almost 90% of women diagnosed with cervical cancer are under-screened [7] , despite a comparatively small state population of 5 million and an excellent cervical screening program. Accordingly, the renewed NCSP will allow under-screened or never-screened women to self-collect for HPV nucleic acid testing. The requirements are not yet finalised but it is proposed that women must be more than 2 years overdue for cervical screening to qualify. Self-collection will take place in a health service setting after consultation with a health practitioner. Women will be invited to attend and offered a speculum examination and Pap screen, with self-collection offered to those who decline.
We used dry flocked swabs for self-collection, which were resuspended in 4 mL of PreservCyt® once the sample arrived at the testing laboratory. Marathon Health provides care to the local community including Aboriginal women in a rural area of New South Wales, and 57 Aboriginal women agreed to take their own samples for HPV testing using a dry flocked swab. Results to date for this small number are: 1 HPV16 positive (1.75%), 1 HPV18 positive (1.75%), 6 non-HPV16/18 positive (10.5%), 40 not detected (70.2%), and 9 invalid results (15.8%). This rate of invalid results is of concern, since other studies have shown that underscreened women are less likely to return for a follow-up test following an invalid result, so they remain under-screened (Posters 59 and 59A show further information). In view of interest in point-of-care testing, we re-tested these samples using Xpert®. Definitive results were concordant except for three of the invalid results which became not detected, one which became HPV16 positive leading to colposcopy, and one which became Table 2 .
An important point is that the four remaining invalid results were genuinely invalid due to lack of cellular material in the samples. If tested using an assay lacking a cellularity control, these women would have been given negative results and wrongly advised to come back for re-testing in 5 years.
Summary and conclusion
The renewed NCSP will be the first open-platform screening program in the world. In our laboratory, prior to 1 December 2017, we will have five of the six HPV testing technologies likely to be available for the program. We are considering a 'horses for courses' approach and while Xpert® HPV might not be the easiest solution for 1200 samples a day, preliminary data suggest it may offer apparent advantages for point-of-care screening or self-collection.
The new NCSP acknowledges that a screening program only works if people use it, and seeks to address this by offering a selfcollection-based alternative pathway. Self-collected samples appear to have a higher rate (around 14-18% depending on population) of oncogenic HPV positivity, and Xpert® HPV appears less likely to give invalid results for such samples than the cobas® 4800 HPV test. 
Background
Papua New Guinea (PNG) is a low-middle-income country and the largest nation in Oceania. Among many problems in women's health, cervical cancer is the most common cancer and the largest cause of cancer deaths. It is estimated that PNG has one of the highest global burdens of cervical cancer, with incidence 6.3 times that of Australia and New Zealand (age standardised rates 34.5 vs 5.5/100,000), and mortality 13.5 times greater (21.7 vs 1.6/100,000). Despite intensive effort over the past 15 years, a non-governmental organisation-led Pap test programme achieved very limited coverage. Moreover, the challenging geography and context of PNG, with limited road infrastructure, mobile phone networks and postal systems, make it difficult to re-trace women identified as having high-grade disease. Following a review of the programme in 2009, a ministerial task force recommended evaluation of alternative approaches such as 'screen and treat'. 
Summary of findings
There was excellent agreement between self-collected vaginal and clinician-collected cervical specimens on PoC Xpert® HPV for the detection of underlying high-grade squamous intraepithelial lesions or above (HSIL) found on liquid-based cytology. VIA alone showed reasonable specificity but its sensitivity was low in comparison with PoC Xpert® testing for any high-risk HPV (hrHPV). A combined algorithm based on PoC Xpert® HPV testing followed by VIA for women testing positive showed higher specificity but much lower sensitivity than HPV testing alone. Selecting for HPV types 16/18/45 did not improve algorithm performance compared with performance based on any hrHPV type.
Discussion
Self-collection of specimens for PoC hrHPV testing offers enormous potential for opportunity savings in our setting, where around 12-15% of women have an hrHPV infection. Women who test hrHPV negative would not need a pelvic examination and can be advised to return at a later date for repeat testing, enabling scarce clinical resources to be focused on women who test hrHPV positive.
Although in this study testing was performed by a member of the research team, in other studies we have trained clinical staff to conduct such tests without problems, showing this approach is feasible in routine clinical settings.
We found that sequential VIA after hrHPV testing dramatically lowered screening sensitivity compared with hrHPV testing alone. A study in Cameroon gave similar results, with sensitivity of 100.0 (95% CI 79.6-100.0) for HPV testing alone and 33.3 (95% CI 15.2-56.3) for HPV testing followed by VIA [2] . Similar results have also been reported in India [3] . Together, these findings suggest that the most appropriate role of visual inspection in future HPV-based POC 'test and treat' algorithms may be to guide cervical ablation (e.g. by ensuring that cryotherapy or thermo-coagulation ablates the entire transformation zone), rather than being used to inform decisions about who should or should not receive treatment.
In conclusion, a 'screen-and-treat' algorithm based on PoC Xpert® HPV testing of self-collected vaginal specimens had high sensitivity, specificity and predictive value compared with VIA examination alone and with a combined screening algorithm comprising HPV testing followed by VIA. Large-scale evaluation is warranted in PNG and other high-burden, low-income settings, to confirm these findings and to establish the health system implementation requirements, acceptability and cost-effectiveness of this PoC Xpert® HPV 'test and treat' approach. 
Information for women undergoing screening
In response to a question about instructions for women coming for screening about, for instance, reproductive health, sexual practice and implications of hrHPV test results, Heather Cubie said that in Malawi written material is not given out but a clear educational message is delivered by a team of experienced and expert providers, and women have the time to ask as many questions as they wish. A standard flip-chart is used to ensure consistent and understandable information.
Low medium volume
A question was raised as to whether 4-5 mL media volumes were sufficient to prevent sample degradation. A cellularity control might not detect this, given some evidence that a study showing that in urine HPV DNA decays more rapidly than human DNA. Heather
Cubie responded that problems had not been seen and the sample invalidity rate was very low, especially when using Quintips®. David Hawkes mentioned a study at VCS which showed 92% agreement between practitioner-collected cervical flocked swabs left on a bench for a week before addition of preservative with practitionercollected brush samples placed straight into preservative. Further studies were continuing including comparisons between self-and practitioner-collected flocked swabs on a range of hrHPV tests, in order to have reliable data before the start of the renewed national screening programme.
Visualisation with acetic acid following HPV testing
Lynette Denny suggested that visualisation following a positive PoC hrHPV result should be considered as a safety check rather than a diagnostic intervention which presents a barrier to 'screen and treat'. Criteria such as >75% of the cervix showing as aceto-white, evidence of cancer or vaginal wall collapse would indicate women unsuitable for immediate cryotherapy and requiring specialist referral. Andrew Vallely agreed that visualisation was important to ensure the entire transition zone is visible and that lesions can be treated correctly. Philip Castle argued for new terminology to differentiate screening/diagnostic VIA from the same procedure being used after a positive hrHPV test, and suggested visual assessment for treatment or VAT. This would be helpful in emphasising the very different purpose of the examination to wider non-specialist audiences.
Silvia Franceschi expressed concerns that while pre-treatment visualisation was clinically logical, its continued use would be a strong obstacle to 'screen and treat' programmes because of the need for trained and experienced staff. Louise Kuhn responded that while VIA-based screening programmes had encountered this problem, hrHPV testing followed by visual assessment for treatment offered the advantage of screening out the 80% or so women who test negative. Only women testing positive would need examination, requiring a considerably smaller staff resource. Heather Cubie emphasised the importance of not only initial but continued regular training and at least annual assessment of competence for staff performing visualisation.
